Associations between Body Mass Index and Breast Cancer Markers

Updata:01-01-1970

Source:
By:Author(s)

DOI: https://doi.org/10.30564/jor.v2i1.2007

Abstract:
Body mass index (BMI) and breast cancer biomarkers (BCBs) such as
resistin, leptin adiponectin, monocyte chemoattractant protein-1 (MCP-1)
and homeostasis model assessment of insulin resistance (HOMA-IR) are
highly associated with each other. The report has focused the inter-rela
tionship between BMI and BCBs based on probabilistic modeling. It has
been shown that mean BMI is directly associated with leptin (P<0.0001)
and MCP-1 (P=0.0002), while it is inversely associated with adiponectin
(P=0.0003), HOMA-IR (P<0.0001), and it is higher for healthy women
(P=0.0116) than breast cancer women. In addition, variance of BMI
is inversely associated with resistin (P=0.1450). On the other hand,
mean MCP-1 is directly associated with BMI (P<0.0001). Mean re
sistin is directly associated with the interaction effect of BMI and leptin
(BMI*Leptin) (P=0.0415), while its variance is directly associated with
BMI (P=0.0942), and it is inversely associated with BMI*Adiponectin
(P=0.1518). Leptin is directly associated with BMI (P<0.0001). Also
adiponectin is inversely associated with BMI (P<0.0001), BMI*Leptin
(P=0.1729), while it is directly associated with Age*BMI (P=0.0017)
and BMI*Resistin (P=0.0615). It can be concluded that BMI and BCBs
are strongly associated with each other. Care should be taken on BMI for
breast cancer women.
References:

[1]Williams CL, Hayman LL, Daniels SR, Robinson TN, Steinberger J, Paridon S, Bazzarre T. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation, 2002, 106(1): 143-160. [2]US Dept Health and Human Services. The Surgeon General’s Call to Action to Prevent and Decrease Overweight and Obesity. Rockville, MD: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General, 2001. [3]National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res., 1998. 6 (suppl 2): 51-209S. [4]Gunter MJ, Xie X, Xue X, Kabat GC et al. Breast Cancer Risk in Metabolically Healthy but Overweight Postmenopausal Women. Cancer Res. 2015, 75(2): 270-274. [5]Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst., 2003, 95(16): 1218-1226. [6]International Agency for Research on Cancer, World Health Organization. Weight control and physical activity. In: Vainio H, Bianchini F, eds. International Agency for Research on Cancer handbooks of cancer prevention, Lyon, France: IARC Press, 2002, 6. [7]Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med., 2003, 348: 1625-1638. [8]Van Den Brandt PA, Spiegelman D, Yaun SS et al. Pooled analysis of prospective cohort studies on height, weight, and breastcancer risk. Am J Epidemiol., 2000, 152: 514-27. [9]Morimoto LM,White E, Chen Z et al. Obesity, body size, and risk of postmenopausal breast cancer: TheWomen’s Health Initiative (United States). Cancer Causes Control, 2002, 13: 741-51. [10]Lahmann PH, Hoffmann K, Allen N et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and nutrition (EPIC). Int J Cancer, 2004, 111: 762-71. [11]Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Bodymass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 2008; 371:569-78. [12]Cecchini RS, Costantino JP, Cauley JA et al. Body mass index and the risk for developing invasive breast cancer among high risk women in Nsabp P-1 and Star Breast Cancer Prevention Trials. Cancer Prev Res (Phila), 2012,5: 583-92. [13]Macis D, Guerrieri-Gonzaga A, Gandini S. Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. International Journal of Epidemiology, 2014: 1226-1236. [14]Dumitrescu RG, Cotarla I. Understanding breast cancer risk - where do we stand in 2005? J Cell Mol Med., 2005, 9: 208-221. [15]Crisóstomo J, Matafome P, Santos-Silva D, Gomes AL, Gomes M, et al. Hyperresistinemia and metabolic dysregulation: a risky crosstalk in obese breast cancer. Endocrine, 2016, 53(2): 433-442. [16]Patrício M, Pereira J, Crisóstomo J, Matafome P, Gomes M, Seiça R, Caramelo F. Using Resistin, glucose, age and BMI to predict the presence of breast cancer. BMC Cancer, 2018, 18(1): 18-29. [17]Paz-Filho G, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci., 2011, 16: 1634-1650. [18]Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, et al. Thehormoneresistin links obesity to diabetes. Nature, 2001, 409: 307-312. [19]Das RN, Lee Y, Mukherjee S, Oh S. Relationship of body mass index with diabetes & breast cancer biomarkers. J Diabetes and Management, 2019,. 9(1): 163-168. [20]Kim J, Das RN, Lee Y, Sahoo RK. Association of monocyte chemoattractant protein-1 with age, glucose, BMI, insulin and other breast cancer biomarkers. Oncology and Radiotherapy, 2019, 13(1): 005-009. [21]Das RN, Lee Y. Association of Serum Adiponectin with Age, BMI and Other Breast Cancer Biomarkers. J Blood Lymph, 2018, 8(4): 233. [22]Das RN, Lee Y. Association of resistin with BMI, age diabetes and breastcancer biomarkers. Journal of Oncology Research and Treatment, 2019, 4(1): 135. [23]Das RN, Lee Y. Relationship of leptin with glucose, BMI, age, insulin and breast cancer biomarkers. Arch Gen Intern Med., 2019, 3(1): 01-03. [24]Lee Y, Nelder JA, Pawitan Y. Generalized Linear Models with Random Effects (Unified Analysis via H-likelihood). Second Edition, London: Chapman & Hall, 2017. [25]Das RN, Lee Y. Log-normal versus gamma models for analyzing data from quality-improvement experiments. Quality Engineering, 2009, 21(1): 79-87. [26] Lesperance ML, Park S. GLMs for the analysis of robust designsvwith dynamic characteristics. Journal Quality Technology, 2003, 35: 253-263.

Tags: